Citations
-
Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. (09 May 2012)
-
Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. (08 May 2012)
-
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. (08 May 2012)
-
FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone as First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer. (08 May 2012)
-
Trastuzumab containing regimens for early breast cancer. (08 May 2012)
-
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. (03 May 2012)
-
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. (25 April 2012)
-
Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. (25 April 2012)
-
Columnar cell lesions on breast needle biopsies: is surgical excision necessary? A systematic review. (18 April 2012)
-
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. (08 April 2012)
-
Cancer genetic risk assessment for individuals at risk of familial breast cancer. (21 March 2012)
-
The effects of psychoeducation and telephone counseling on the adjustment of women with early-stage breast cancer. (21 March 2012)
-
Comparison of radioguided occult lesion localization (ROLL) and wire localization for non-palpable breast cancers: A meta-analysis. (15 March 2012)
-
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. (29 February 2012)
-
Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. (29 February 2012)
-
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer. (26 February 2012)
-
Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. (24 February 2012)
-
Quality of life and symptom experience in breast cancer survivors after participating in a psychoeducational support program: a pilot study. (20 February 2012)
-
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. (13 February 2012)
-
Bevacizumab added to neoadjuvant chemotherapy for breast cancer. (13 February 2012)
